A Novel Catheter System for Totally Implantable Intravenous Drug Therapy: Assessment of Catheter Function and Patency with Trepostinil Therapy

Abstract

The Model 10642 vascular catheter along with the SynchroMed II implantable drug delivery system showed promising performance in a chronic animal model.

Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System

“…DelIVery for Pulmonary Arterial Hypertension was a multicenter, prospective, single-arm clinical trial using an investigational implantable drug delivery system conducted at 10 US centers. The implantable drug delivery system consisted of the model 10642 Implantable Intravascular Catheter, 5 the model 8637 SynchroMed II implantable drug delivery pump, and the model 8840 N'Vision programmer (Medtronic, Inc).…”

“…Limitations with current prostanoid delivery systems prompted a clinical trial (DelIVery for Pulmonary Arterial Hypertension) to determine if a fully implantable, programmable delivery system could safely administer treprostinil (Remodulin, United Therapeutics Corporation) to patients with PAH. Treprostinil was chosen because it is stable at body temperature 5 and has a longer plasma half-life (w4 h 6 ) than epoprostenol.…”

Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension

“…Concerning flow rates, a proper intravenous catheter function at a flow rate of 540 mL per day of treprostinil or saline was demonstrated in a dog model. 11 Moreover, Tapson et al reported that even lower flow rates of intravenous treprostinil, ranging between 100 and 200 mL/hour, are feasible in patients with PAH. 12 The maximal number of days the pump delivers treprostinil can be determined by the calculation: 40 mL ½max: refil volume=flow rate ½mL=day ¼ maximum number of pump running days…”

Innovative application of an implantable venous access system in the portal vein: technique, results and complications in three dogs

“…In veterinary medicine the use of VAP systems is not common practice and literature on applications has been limited. Due to the reduced risk of infection, the limited chance for dislodgement and the ability to provide minimally invasive vascular access for repeated and long-term use, implantable VAP systems were previously suggested for both animal and human use [4–6]. VAP systems in the dog and cat can be valuable tools in experimental research, but also have clinical potential in veterinary medicine [4, 7–10].…”

“…Due to the reduced risk of infection, the limited chance for dislodgement and the ability to provide minimally invasive vascular access for repeated and long-term use, implantable VAP systems were previously suggested for both animal and human use [4–6]. VAP systems in the dog and cat can be valuable tools in experimental research, but also have clinical potential in veterinary medicine [4, 7–10]. VAP systems are described to be useful for chronic intravenous drug therapy, long-term use of chemotherapeutics and blood sampling [4, 11, 12].…”